Trial Profile
Randomised, double-blind, placebo-controlled Phase I study to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of orally inhaled PB01 administered to healthy subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jul 2016
Price :
$35
*
At a glance
- Drugs PB 01 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Paranta Biosciences
- 08 Jul 2016 New trial record